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he observation that a large majority of psychi-
atric patients smoke cigarettes leads to the question
about the possible relationship between smoking,depen-
dence,and neurological diseases.
1,2 Several studies have
reported an association between smoking and depres-
sion.
3,4This question takes on a new dimension when we
consider that nicotine,the natural alkaloid contained in
tobacco leaves, is a powerful and addictive compound
acting on the central nervous system (CNS).
A pivotal point in this line of thinking is what we know
about the mechanisms by which nicotine acts on the CNS
and what we can gain from a better understanding of the
intimate processes that drive to tobacco consumption.
5,6
In this article,we will examine the basic functioning of
the key players in nicotine addiction, ie, the neuronal
nicotinic acetylcholine (ACh) receptors,and their possi-
ble role in depression.
The ACh receptors
First called Vagustoff by Loewi,due to its discovery in the
heart muscle in 1921, the neurotransmitter ACh exerts
many different actions.ACh is synthesized in the terminal
bouton and stored in clear vesicles, and is released by
nerve activity in the synaptic cleft.After a rapid increase,
the ACh concentration quickly declines due to rapid
hydrolysis (catalyzed by the enzyme acetylcholinesterase)
and diffusion.The determinant role of this enzymatic activ-
ity in regulating the cholinergic tone and its brain function
was revealed more than 150 years ago,well before the dis-
covery of ACh,with the use of compounds that were later
shown to be centrally active anticholinesterase agents.
7,8
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Although tobacco use and smoking were introduced
long ago, it was only recently that the nicotine con-
tained in the tobacco leaves was recognized as an addic-
tive substance acting on the central nervous system
(CNS). However, even prior to this recognition, several
studies have reported an association between smoking
and psychiatric disorders. One of the many observations
was that smoking cessation is accompanied by a marked
increase in the probability of major depression. In par-
allel with the discovery of the neuronal nicotinic acetyl-
choline receptors and their extensive expression in the
CNS, this association sheds new light on the influence of
cholinergic transmission in depression. In this article, we
examine the various modes of action of nicotine in the
CNS and discuss the mechanisms by which this alkaloid
can prevent or precipitate mood disorders, and the pos-
sibility of discovering new therapeutic avenues for the
treatment of depression.
© 2005, LLS SAS Dialogues Clin Neurosci. 2005;7:207-216.The observation that injection of physostigmine causes a
rapid modification of mood and temporarily reverses
acute mania suggested a possible hypersensitivite cholin-
ergic equilibrium.
9,10 Although these studies shed a new
light on variations in cholinergic tone,they could not tell
which receptors were stimulated by the sustained increase
in ACh.With progress in molecular biology and genetics,
we now know that ACh acts on two types of receptors:the
muscarinic receptors and the nicotinic receptors.
The muscarinic ACh receptors
The muscarinic ACh receptors belong to the superfam-
ily of G-coupled proteins, which display the structural
characteristics of seven transmembrane proteins (Figure
1A).
11 Five genes encoding muscarinic receptors have
been identified to date,and their chromosomic localiza-
tion determined.Binding of ACh stabilizes the receptor
in a conformation that activates G-proteins present in
their vicinity. A further subdivision of the muscarinic
receptors in two groups can be made as a function of the
second-messenger pathways activated: (i) M1 to M3,
which stimulate the hydrolysis of phosphoinositol and
trigger an increase in intracellular calcium concentration
together with cyclic adenosine monophosphate (cAMP);
and (ii) M4 to M5,which inhibit adenylyl cyclase.
12
The nicotinic ACh receptors
Neuronal nicotinic ACh receptors (nAChRs),which will
be discussed here,belong to the family of ligand-gated
channels.These receptors constitute both the ligand-bind-
ing site and the ionic pore through which ions can flow
when the receptor is stabilized in the open conformation.
Historically, the existence of such receptors was first
revealed in 1857 by Bernard,who showed that the poi-
son curare blocks transmission at the neuromuscular
junction,but does not prevent muscle contraction elicited
by electrical stimulation.Since this observation,the neu-
romuscular junction has been used as a reference for
synaptic transmission in physiology and pharmacology.
It was also recognized a long time ago that ACh is the
neurotransmitter that acts on the parasympathetic gan-
glia,but little was known about the precise mechanisms
underlying this neurotransmission. Although electro-
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Selected abbreviations and acronyms
ACh acetylcholine
cAMP cyclic adenosine monophosphate
GABA  -aminobutyric acid
HPA hypothalamic-pituitary-adrenal (axis)
5-HT 5-hydroxytryptamine (serotonin)
nAChR neuronal nicotinic acetylcholine receptor
Figure 1. Schematic representation of the cholinergic receptors in the
plasma membrane. A. Side view of the muscarinic receptor with
a G-protein complex. Note the N- and C-terminal end of the
protein with its seven transmembrane segments. The acetyl-
choline (ACh) binding site is thought to be in the center of the
receptor complex. B. Side view of the nicotinic ACh receptor.
The receptor represented corresponds to the α4β2, which is
thought to be the major brain high-affinity nicotinic receptor.
Note the subunit arrangement with the axis of symmetry and
the ionic pore that is formed in the center of the assembly. The
ACh binding site is at the interface between two adjacent α-β
subunits.
C
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Aphysiological experiments in the 1950s
13 showed that the
pharmacology of ganglionic receptors differs from that
of the neuromuscular junction,
14 a clear distinction
between the structure and function of these receptor
classes had to await progress in molecular biology.
Cloning and sequencing of the genes that encode the
neuromuscular junction receptors revealed that embry-
onic muscle receptors result from the assembly of five
subunits in the stoichiometry α2,β,γ,and δ,while adult
receptors are made from α2, β, ε, and δ.
15 Sequence
homologies and low-stringency hybridization soon led
researchers to clone a series of genes encoding for pro-
teins that resemble those of the neuromuscular junction
receptors,but displaying significant differences.To date,
12 genes encoding for α2 to α10 and β2 to β4 have been
isolated in vertebrates and their chromosomic localiza-
tion identified.Following an international agreement,the
nomenclature between α and  β subunits was made
according to specific sequences of these proteins,with α
subunits showing the highest degree of homology with
their muscle counterpart and the presence of two adja-
cent cysteines in the N-terminal extracellular domain.
16
It is widely accepted that nAChRs result,as the muscle
receptors, from the assembly of five subunits, each of
which spans the membrane four times (Figure 1B).
15,17,18
This basic structural feature is common to a series of lig-
and-gated channels,which include the serotonin recep-
tor 5-HT3, zinc-activated protein (ZAC), the glycine
receptors,and the γ-aminobutyric acid (GABA) recep-
tors GABAA and GABAC. The large extracellular
domain comprises the ligand-binding site and the ionic
pore lies in the center of the assembly.Each of the five
subunits lines the pore by its second transmembrane
domain.Despite the lack of a full crystal structure of the
nAChRs, it is believed that the natural ligand ACh or
nicotine binds at the interface between two adjacent sub-
units in the extracellular domain.Thus,the contribution
of two adjacent subunits to the formation of the ligand-
binding domain implies that both subunits will define the
physiological and pharmacological properties of the
resulting receptor.Although some subunits such as α7
can assemble in a homomeric manner, most receptors
result from the heteromeric assembly of at least two sub-
units,for instance α4β2.In the case of heteromeric recep-
tors,a further complexity can arise for triplet combina-
tions, such as α4α6β2, etc. This gives rise to a wider
diversity of the receptor function,which correlates with
the pattern of expression of the different subunits.
Binding of an agonist stabilizes the receptor in the active
open state and causes cations to rapidly diffuse across the
minute ionic pore.Significant differences in physiologi-
cal properties,in terms of sensitivity to the agonist and
time course of response, can be observed between dif-
ferent subtypes of nAChRs.One extreme is the α7 recep-
tors,which have a low sensitivity to ACh,but a very fast
response; the other extreme is receptors like the α4β2
receptor,which is highly sensitive to ACh and nicotine,
but has a slow response (Figure 2A).As illustrated in
Figure 2, α7 responses are phasic,while α4β2 responses
are tonic.An additional and characteristic feature of α7
nAChRs is their high permeability to calcium ions.
19,20
Since these divalent cations have been shown to play an
important role as a second messenger,it can be expected
that α7 activation could modify neuronal activity or gene
expression.
While a brief agonist exposure activates nAChRs,a sus-
tained exposure to an agonist provokes a slow desensiti-
zation and therefore inhibits subsequent agonist-evoked
responses.Figure 2 illustrates the typical protocol used to
assess desensitization to prolonged nicotine exposure
together with the dose–response inhibition curve.
Superposition of the desensitization and activation
curves indicates that there is a small window in which a
ligand such as nicotine can provoke sustained receptor
activation. On the basis of the nicotine concentration
determined in the cerebrospinal fluid (CSF) of smokers,
21
which can reach 100 to 200 nM,it is possible to deduce
that nicotine should cause a small but sustained receptor
opening.The activation and desensitization profiles are
specific for each nAChR subtype.
Receptor distribution
To understand the possible contribution of nAChRs in
the CNS function, it is essential to know their precise
brain and cellular distribution.Receptor labeling relies
either on the use of specific ligands or antibodies.
22,23
Alternatively,receptors can be labeled in vivo using brain
imaging techniques,such as positron emission tomogra-
phy (PET).PET studies in monkey and human using A-
85380, a ligand that preferentially labels the α4β2
nAChRs, reported significant labeling in the thalamus
and more diffuse labeling in the cortical areas.
24-26While
these results demonstrate the importance of heteromeric
receptors in human brain,it should also be noted that a
significant labeling is observed when the toxin from the
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binds to the muscle and the α7 receptors, is used.
23,27,28
[
125I]α-Bgt studies have shown that α7 is widely distrib-
uted in mammalian brain and that its area of expression
differs from that of α4β2.
23,28
To better understand the function,however,we need to
know the subcellular distribution of the receptors.While
it is beyond the scope of this work to enter into details of
receptor distribution, it is important to know that the
expression of nAChRs is not restricted to the synaptic
cleft and that a high density of receptors is observed on
the cell body,as well as in the presynaptic and/or extrasy-
naptic areas (Figure 3).Moreover,the presynaptic and
extrasynaptic localization of the nAChRs has been
shown to play an important role in the modulation of
neurotransmitter release and neuronal activity.
29-31
Multiple functions of nAChRs
The broad distribution of nAChRs in the CNS suggests
that these receptors play a major role in brain physiol-
ogy.Surprisingly,however,bath application of nicotine to
brain slices produces little or no effect,a result that was
interpreted as the lack of action of nicotine in the CNS.
However,if the neuronal properties are examined more
closely, the action of nicotine can be detected in most
brain areas.The reason for this discrepancy is mainly due
to the method of drug application.When applied in the
bath, nicotine provokes both a small activation of the
receptors and their desensitization.Because bath appli-
cation is rather slow,the short-lasting activation is essen-
tially masked by the receptor desensitization.In contrast,
when an agonist such as ACh or nicotine is briefly
applied to neurons the physiological consequences of the
nAChRs can be detected.
It has been shown that activation of nAChRs causes mul-
tiple effects according to the localization of the receptor.
For example,somatic receptors will cause a depolariza-
tion of the neuron and therefore modulate its firing activ-
ity,while presynaptic receptors modulate the release of
other neurotransmitter,such as dopamine,glutamate,and
5-HT.
31To understand the basis of these neurotransmit-
ter interactions, it should be recalled that a significant
fraction of the nAChRs are expressed on presynaptic
Basic research
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Figure 2. A. Schematic representation of typical acetylcholine (ACh)
evoked currents recorded in cells expressing the α4β2 (left trace)
or α7 (right trace) receptors. B. Upper panel. Typical protocol
used to determine the inhibition caused by a sustained nicotine
exposure. The cell is challenged at periodic time intervals with a
brief test pulse of agonist at low concentration. Having estab-
lished that the cell response is stable, a sustained concentration
of nicotine concentration comparable to that found in the
smoker’s brain is applied to the bath. Note the progressive
decline of the responses that stabilizes after about half an hour.
Lower panel. Plot of the fraction of response as a function of the
logarithm of the nicotine concentration yields a typical inhibi-
tion dose–response curve that can be compared to the activa-
tion profile.
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Bboutons.Activation of the nAChRs causes two important
mechanisms that are (i) depolarization of the synaptic
bouton;and (ii) in the case of α7 nAChRs,a significant
calcium influx.Both mechanisms provoke an increase in
the intracellular calcium concentration,which is known
to be the key step in the liberation of the neurotransmit-
ter contained in the vesicle of the synaptic bouton by
exocytosis.
While a few experiments have shown that nAChRs can
participate in synaptic transmission, it is generally
accepted that these receptors have more a modulatory
role in neuronal function,rather than a determining role
in the fast excitatory pathways.In agreement with these
observations, knocking out a given nAChR subunit in
mice is not lethal,but was shown to alter behavior.
32
Nicotine and depression
In view of the modulatory role of nAChRs and their mul-
tiple interactions with various neurotransmitter systems,
such as dopamine or 5-HT, it is not surprising that an
association between nicotine and depression is often
reported.
3,4The main pathways associating nicotine and
depression are summarized in Table I.During the past
5 years,more than 250 scientific publications have dis-
cussed the interaction between nicotine and depression.
The main question that remain open is by which mecha-
nisms nicotine could act on the mood and/or depression.
To examine this point further,we shall discuss a series of
hypotheses that could explain the reported association
between nicotine and depression.
Pharmacology of the receptor
Some compounds commonly used to treat depression,
including tricyclic antidepressants such as imipramine
and amitriptyline,have been shown to inhibit the reup-
take of biogenic amine and thereby cause accumulation
of neurotransmitters in the synaptic cleft.The relatively
small molecular structure of these molecules and their
tricyclic nature indicate that their effects may not be
restricted to reuptake inhibition and that they may inter-
act in other physiologically important ways.
Another structural feature of these molecules can be
deduced from experiments with phenothiazine deriva-
tives,such as chlorpromazine (a major antipsychotic used
to treat schizophrenia). Earlier reports that chlorpro-
mazine can enter the ionic pore of the muscle nicotinic
receptor and be used to label amino acids that line that
pore
33 prompted further investigation on the possible
action of tricyclic molecules on nAChRs.According to
the muscle receptor data,imipramine and desipramine
inhibit the nAChRs and concentrations as low as 0.17 µM
are sufficient to halve the receptor activity.
34 Similarly,it
was shown that,in the micromolar range,clomipramine
inhibits the α4β2 receptor subtype,which is known to be
expressed in the CNS.
35 Furthermore,it was also shown
that buproprion and phencylidine inhibit nicotinic recep-
tors in cell lines and in brain slices in a noncompetitive
manner.
36,37
Therefore,the first indication of the mode of action of tri-
cyclic molecules was provided by the fact that chlorpro-
mazine can be used to label amino acids supposed to be
in the ionic pore.
33 Detailed voltage clamp analysis of the
mode of action of noncompetitive blockers,including tri-
Neuronal nicotinic acetylcholine receptor and depression - Bertrand Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
211
Table I. Main pathways influenced by nicotine believed to be associated
with depression.
Cortex
Hippocampus
Thalamus
Hypothalamic-pituitary-adrenal (HPA) axis
Mesolimbic system
Figure 3. Schematic representation subcellular localization of neuronal
nicotinic receptors with their postsynaptic, presynaptic, extrasy-
naptic, and axonal distributions. 
Postsynaptic
Axonal
Presynaptic
Extrasynapticcyclic compounds, confirmed that these molecules can
enter the ionic pore of the human neuronal nicotinic
receptor α4β2 and block the channel conduction by steric
hindrance.
38 Additional experiments carried out in rat
brain slices further confirmed the effects of monoamine
blockers on rat brain slices, which revealed inhibitory
mechanisms in the low micromolar range.
39 Molecules
structurally related to the classical tricyclic reuptake
inhibitors also include the well-known antiepileptic drug
carbamazepine.It was shown that carbamazepine blocks
nAChRs at a concentration that is found in the CSF of
patients being treated with this drug.
40 Interestingly,it was
found that some mutations of the α4 subunit of the nico-
tinic receptor found in patients suffering from genetically
transmissible nocturnal epilepsy exhibit a higher sensi-
tivity to carbamazepine.
40 In addition,the more specific
5-HT reuptake inhibitor fluoxetine was also found to
interact with nicotinic receptors at concentrations as low
as 0.57 µM.
41
Altogether these data suggest that inhibition of the
nAChR might contribute to the antidepressant action of
these particular agents.The question that remains is how
blockade of these ligand-gated channels could account for
a beneficial outcome on the depressive status of the
patients.The use of a broad-spectrum blocker of the nico-
tinic receptors,mecamylamine,which is devoid of action
on monoamine reuptake,may provide a first indication,
especially since it was found to have a beneficial effect in
the treatment of depression.
42,43 The hypothesis is that
depression is accompanied by hypercholinergic activity.
42,43
Nicotinic receptors and the HPA axis
Mood disorders, which include depression, are often
thought of as a dysfunction or imbalance of the hypo-
thalamic-pituitary-adrenal (HPA) system.The two major
contributions with opposing modulation of the HPA are
the amygdala,with a positive action,and the hippocam-
pus,with a negative feedback.We should therefore con-
sider three features of the nicotinic receptors in the HPA
system:
•The high level and diversity of neuronal nicotinic
receptor expression in both hippocampus
27,28 and amyg-
dala.
44
•The importance of nAChRs in the hypothalamus cir-
cuits.
45
•The fact that steroids and mineralocorticoids modulate
the nAChRs function.
46-48
While both amygdala and hippocampus have a large
number of nicotinic receptors,more attention was paid
to studies of nicotinic receptor function in the hip-
pocampus.
31,49 However, given the complexity of hip-
pocampal circuits and the multiple effects of acute and
chronic nicotine exposure,the main outcome of nAChR
stimulation remains to be elucidated.Despite our incom-
plete understanding of nicotine’s action on the amygdala
and hippocampus circuitry,there is no doubt that expo-
sure to this agent will alter the network activity and may
cause an imbalance of the HPA.
Histological analysis of the hypothalamus revealed that
this brain area has a high level of nAChR expression.
28
Moreover,the functionality of these receptors in the par-
aventricular nucleus has been demonstrated by electro-
physiology.
50 Parvocellular and magnocellular neurons
that project to the anterior and posterior areas of the
pituitary, respectively, have been shown to respond to
ACh or nicotine.
50 In an attempt to study effects of nico-
tine withdrawal in an animal model,rats were implanted
with minipumps dispensing nicotine.HPA activity was
determined on the second day after withdrawal of nico-
tine using the stress-induced corticosterone response and
the dexamethasone suppression test.
51 The results
obtained by these authors suggest that the lower sensi-
tivity of the HPA axis to stress during nicotine with-
drawal may trigger depression during smoking cessation,
but glucocorticoid receptor and corticotropin-releasing
hormone do not appear to play a significant role in the
condition tested.Although our knowledge of the role of
the nAChRs in the parvocellular neurons is far from
complete, these data demonstrate unequivocally that
nicotine can modify the activity of these neurons and
could,thereby,change the HPA equilibrium.
The first evidence of a direct action of steroids on
nAChRs came from the observation that ACh-evoked
currents recorded in cells expressing the α4β2 nAChR are
inhibited in a noncompetitive manner by progesterone.
52
Following this initial observation,it was shown that this
inhibition is mediated by an allosteric interaction of
steroids with this subtype of nAChRs. It was also
observed that steroids inhibit the function of the α7
receptors. Further studies revealed that, while proges-
terone inhibit the rat or human α4β2 nAChRs,the neu-
rosteroid 17β-estradiol markedly enhances the response
of these receptors.
48 These workers also revealed the
determinant contribution of the short peptide segment
of the human α4 subunit C-terminal end.
46,48
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Steroids and neurosteroids have also been shown to
modulate the inhibitory GABAA receptors and some act
through comparable protein interactions.
53Altogether,
these data therefore support the correlation reported
between neurosteroids and psychopathology.
54When we
examine the HPA system,it is important to recall that the
adrenal medulla is part of the sympathetic division,but
with the particularity that preganglionic fibers terminate
directly in the gland.Thus,ACh is the principal neuro-
transmitter that mediates signaling between the nerve
and the gland activity. Moreover,ACh released by the
preganglionic fibers is known to activate neuronal nico-
tinic receptors that result from the assembly of the α3 and
β4 subunits.In view of the rather high level of circulating
nicotine and its multiple effects on both central and
peripheral receptors,the modification of the regulatory
circuits of the adrenal gland should not be ignored.
Stress and dramatic changes in hormone levels in post-
partum women are often thought to be at the origin of
what is now called “postpartum depression.” Despite
some association between postpartum depression and
smoking,the evidence remains weak,and more thorough
studies are needed to reach what is an otherwise tempt-
ing conclusion.Although progress has been made in our
understanding of the endocrinology leading to hormone
therapy and introduction of a wider set of drugs available
to a larger fraction of the population,hormone substitu-
tion or addition continues to raise a number of concerns.
55
Smoking and depression
The association between smoking and depression has been
reported in many studies.
3,4 Moreover, the relationship
between smoking and depression is bidirectional and
genetic factors may account up to 67% for smoking initia-
tion,maintenance,and dependence.Notwithstanding,the
mechanisms that link smoking and depression are still
poorly understood as several factors are acting concomi-
tantly.One hypothesis is that,while,at first,nicotine may
exert an anxiolytic effect,its prolonged consumption may
switch its action to an anxiogenic effect.To understand how
the same compound may act differently as a function of
time,it is necessary to examine effects of prolonged nico-
tine exposure.Postmortem studies in human brain from
smokers and nonsmokers revealed a surprising result.
56
Namely, a marked difference in the amount of nicotine
binding was observed,with an increased binding in smok-
ers’ brains versus nonsmokers’.This observation contra-
dicted the initial theory that a progressive increase in
tobacco consumption could be attributed to a reduction in
the receptor number,such as that observed in other drugs
of abuse and the accompanying so-called downregulation.
These studies triggered a renewal of interest in the effects
of prolonged nicotine exposure.Chronic exposure to nico-
tine has also been shown to cause a differential upregula-
tion of the specific receptor subtypes accompanied by
selective expression of receptor subtypes in different
areas.
57,58Although nicotinic ACh receptor upregulation is
a well-accepted phenomenon,debate still exists about the
molecular mechanisms that cause such upregulation.
To better understand the outcome of chronic nicotine
exposure, it may be necessary to understand the func-
tional status of receptors that are chronically exposed to
low agonist concentrations. Use of cells that stably
express the human α4β2 nAChRs provided a first set of
clues.
59The functional properties were investigated using
intracellular recordings and fast agonist application.This
revealed that, while the responses of receptors are
reduced when recorded in the presence of nicotine,there
was a significant increase in cell response and an increase
in receptor sensitivity to ACh.These results indicate that,
if such mechanisms exist in vivo, chronic exposure to
nicotine should cause a dual modification of the physio-
logical properties of nAChRs with,on the one hand,an
inhibition when the receptor is exposed to nicotine and,
on the other,an increase in response upon removal of the
drug.In support of the importance of nicotine effects,a
single injection of nicotine in the rat was shown to cause
a modification of the physiological properties of nicotinic
receptors expressed in hippocampus within a few hours.
36
Taken together these data indicate that chronic nicotine
exposure triggers a number of cellular processes that
induce physiological changes, the outcome of which is
specific to the particular subtypes of nicotinic receptors
expressed in a given brain area. In addition, prenatal
exposure to nicotine transmitted by the mother in the
fetal circulation was shown to be sufficient to cause
detectable changes in rats.
60 Low concentration of this
alkaloid in milk was also found to be sufficient to trigger
detectable changes in the level and pattern of receptor
distribution in the brains of babies.
61This suggests that
long-term memory of drug exposure can significantly
modify brain function and must be taken into account
when analyzing nicotine’s effects.
A further complexity in the effects caused by chronic
nicotine exposure is the modification of gene expressionand alteration of other cellular functions.For example,it
was reported that nicotine causes an increase in the num-
ber of 5-HT transporters in prefrontal cortex and hip-
pocampus.
62This observation could explain the loss of 5-
HT observed in the dorsal hippocampus following
chronic nicotine infusion.Since it is known that the dor-
sal hippocampus may be associated with anxiogenic
effects,a reduction in 5-HT in this brain area would be
expected to cause an anxiolytic effect.
63
Nicotinic receptors and sleep disorders
Another association between nicotine and depression is
provided by the examination of circadian rhythms.Major
depressive disorders are typically characterized by the
alteration of sleep,which is thought to further imbalance
the patient’s equilibrium.On the basis of the observation
that the frequency of major depression is increased dur-
ing nicotine cessation,it was inferred that nicotine could
protect against depression.
64 In support of this hypothe-
sis,it was reported that administration of nicotine might
have beneficial effects on both sleep and depression.
65
Together,the high level of expression of nicotinic recep-
tors in the thalamus and the determinant role of thalam-
ocortical loops during sleep further underline the rele-
vance of the nicotinic receptors in sleep regulation. In
addition, it was recently shown that nicotine inhibits
sleep-promoting neuron activity in rat brain slices.
66
These data illustrate the importance of neurotransmit-
ters in the regulation of sleep and suggest that presence
of nicotine in the brain may modify sleep control.
The importance of nAChRs function during sleep in
humans has been further illustrated by recent genetic
analysis.The finding in humans of an association between
a genetically transmissible form of nocturnal frontal lobe
epilepsy with mutations in the genes that encode for
either the α4 or the β2 subunits of the nAChRs shed a
new light on the contribution of this family of ligand-
gated channels to neurological and sleep disorders.
67To
date, all mutations analyzed in functional studies have
shown an increase in ACh sensitivity.
49,68,69This suggests
that this specific form of epilepsy,which is caused by an
imbalance between inhibition and excitation,is due to an
increase in neuronal nicotinic receptor function.
While providing preliminary evidences of the determin-
ing contribution of neuronal nicotinic receptors in neu-
rological disorders,these findings also indicate that muta-
tions in the genes that encode for neuronal nicotinic
receptors could play a role in other brain dysfunctions,
such as depression.
Conclusions
The state “smoking is dangerous for your health” is
mainly identified by the general population as meaning
that smoking causes cardiovascular and respiratory
impairments,while its relevance for psychiatric and mood
disorders is generally not considered. The association
between smoking cessation and depression is,however,
well recognized by specialists and well documented in
many clinical studies.
An important step in the understanding of nicotine
dependence and the multiple effects caused by chronic
exposure of our brain to this alkaloid was made with the
discovery of an entire family of genes that encode for lig-
and-gated channels,which display a high affinity for nico-
tine and that are widely expressed in the human brain.
Since then,numerous studies have addressed the role of
nAChRs in mammalian brain and they were found to
play an important role in the modulation of neuronal
activity and release of neurotransmitters such as
dopamine,glutamate,or 5-HT.
The identification of interactions between nicotine and
compounds typically used in the treatment of depression,
such as monoamine reuptake inhibitors,sheds new light
on our understanding of the brain pharmacology and
opens up new avenues for research into treatments.
Finally,polymorphisms and mutations identified in genes
encoding for the nAChRs and their association with
sleep and neurological disorders provide compelling evi-
dence for the fast-evolving field of pharmacogenomics,
and reveals individual differences, comparable to the
well-known example of blue or brown eye color, that
must be taken into account in the diagnosis and treat-
ment of the multiple forms of depression. ❏
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Posible contribución de los receptores 
nicotínicos neuronales de acetilcolina 
en la depresión
Aunque el empleo del tabaco y el fumar fueron
introducidos hace mucho tiempo, sólo reciente-
mente se ha reconocido que la nicotina contenida
en las hojas de tabaco constituye una sustancia
adictiva que actúa en el sistema nervioso central
(SNC). Sin embargo, aun previo a este reconoci-
miento diversos estudios habían demostrado una
asociación entre el fumar y los trastornos psiquiá-
tricos. Una de las muchas observaciones fue que el
dejar de fumar se acompañaba de un marcado
aumento en la probabilidad de presentar una
depresión mayor. En paralelo con el descubrimiento
de los receptores nicotínicos neuronales de acetil-
colina y su extensa expresión en el SNC, esta aso-
ciación ha aportado nuevas luces acerca de la
influencia de la transmisión colinérgica en la depre-
sión. En este artículo se examinan varios modos de
acción de la nicotina en el SNC y se discuten los
mecanismos mediante los cuales este alcaloide
puede prevenir o precipitar los trastornos del
ánimo, y la posibilidad del descubrimiento de nue-
vas alternativas para el tratamiento de la depresión. 
Contribution éventuelle des récepteurs 
nicotiniques neuronaux de l’acétylcholine
dans la dépression
Bien que la consommation de tabac soit entrée
dans les mœurs de nos sociétés, il y a plusieurs cen-
taines d’années, ce n’est que très récemment que la
nicotine, qui est présente dans les feuilles du tabac,
a été reconnue comme provoquant une dépen-
dance au niveau du système nerveux central. De
nombreuses études ont mis en évidence des asso-
ciations entre certaines maladies psychiatriques et
le comportement tabagique. L’une de ces associa-
tions est l’augmentation du risque de dépression
majeure chez les fumeurs en sevrage. Les décou-
vertes effectuées dans le domaine de la recherche
fondamentale avec la mise en évidence des récep-
teurs de l’acétylcholine à haute affinité pour la
nicotine dans le système nerveux central ont révélé
des mécanismes jusque-là insoupçonnés sur l’im-
portance du système cholinergique dans les pro-
cessus cognitifs et la dépression. Dans ce travail,
nous examinons les modes d’action de la nicotine
dans le système nerveux central et nous discutons
des mécanismes par lesquels cet alcaloïde peut
empêcher ou précipiter des troubles de l’humeur.
Cette revue a également pour but de stimuler les
réflexions sur de nouvelles voies thérapeutiques
dans le traitement de la dépression.Basic research
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